Olink Explorer >5400
| Location: | Maryland |
|---|---|
| Posted: | Jul 15, 2026 |
| Due: | Jul 25, 2026 |
| Agency: | HEALTH AND HUMAN SERVICES, DEPARTMENT OF |
| Type of Government: | Federal |
| Category: |
|
| Solicitation No: | 75N98026Q00800 |
| Publication URL: | To access bid details, please log in. |
APEX Accelerators are an official government contracting resource for small businesses. Find your local APEX Accelerator (opens in new window) for free government expertise related to contract opportunities.
APEX Accelerators are funded in part through a cooperative agreement with the Department of Defense.
The APEX Accelerators program was formerly known as the Procurement Technical Assistance Program (opens in new window) (PTAP).
- Contract Opportunity Type: Solicitation (Original)
- Original Published Date: Jul 15, 2026 12:12 pm EDT
- Original Date Offers Due: Jul 25, 2026 09:00 am EDT
- Inactive Policy: Manual
- Original Inactive Date: Jul 26, 2026
-
Initiative:
- None
- Original Set Aside: No Set aside used
- Product Service Code: Q301 - REFERENCE LABORATORY TESTING
-
NAICS Code:
- 541380 - Testing Laboratories and Services
-
Place of Performance:
Bethesda , MD 20892USA
Requirements:
2.0 BACKGROUND
Our lab studies the role of inflammation/innate resistance and commensal microbiota in carcinogenesis, cancer progression and therapy of cancer.
The following product features/characteristics are required for this requirement:
Protein Coverage - Measures ~5,400+ human proteins simultaneously in a single workflow.
Technology - Uses Proximity Extension Assay (PEA) with dual antibody recognition coupled to DNA barcoding and next-generation sequencing (NGS) readout.
Sample input – requires only 2 ul of plasma, serum, and other sample types
Specificity - Reported 99.5% specificity with negligible cross-reactivity due to dual-recognition antibody design.
Dynamic Range - Approximately 10 orders of magnitude (fg/mL to mg/mL), enabling detection of both low- and high-abundance proteins.
Key strengths
- Very broad proteome coverage while maintaining antibody-based specificity.
- Excellent sensitivity for low-abundance circulating proteins (especially cytokines and signaling proteins).
- Extremely low sample-volume requirement.
- Highly standardized platform, making it attractive for epidemiology and multi-omics studies.
- 6011 EXECUTIVE BLVD., SUITE 503L
- BETHESDA , MD 20892
- USA
- John Burton
- burtonjo@mail.nih.gov
- Jul 15, 2026 12:12 pm EDTSolicitation (Original)
With GovernmentContracts, you can:
- Find more opportunities and win more business
- Receive daily alerts for all new bid opportunities
- Get contract opportunities matched to your business
See also
...Therapy Active Contract Opportunity Notice ID NIH-NOI-26-PCA-NCI-09516 Related Notice Department/Ind...
HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Bid Due: 7/30/2026
...Therapy Coverage of Nonopioid Drugs Status: Open Due / Close Date: 8/14/2026 Publish ...
State Government of Maryland
Bid Due: 8/14/2026
...mental health therapy services to their existing clients while those students are attending ...
State Government of Maryland
Bid Due: 8/07/2026
...to determine if post-operative corticosteroid therapy improves serum bilirubin and survival without liver... ...
HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Bid Due: 5/31/2029